Neuro, OT - Any thoughts on the Memory Pharma Phase 2 AD results announced today? The market didn't respond very much, but shouldn't these results be good enough for Roche to advance the compound further? Doesn't the nicotinic approach seems like one of the more likely ones to ultimately make it to market for AD? Thanks for any insights.